Key result
Five weeks of riociguat treatment in mice with established heart failure improved LV ejection fraction and decreased LV mass, myocardial fibrosis, and expression of remodelling genes.
Why the study?
Heart failure involves an impaired NO-sGC-cGMP pathway, prompting the hypothesis that sGC stimulation with riociguat prevents pathological cardiac remodelling and heart failure from chronic pressure overload.
Does riociguat improve cardiac function and attenuate pathological remodeling in a mouse model of pressure overload-induced heart failure?
Does riociguat improve cardiac function and attenuate pathological remodeling in a mouse model of pressure overload-induced heart failure?
In a mouse model of pressure overload-induced heart failure, stimulation of soluble guanylyl cyclase with riociguat reversed heart failure and pathological cardiac remodeling.
No takes yet. Share an insight, caveat, or question.
Riociguat attenuates murine pressure-overload remodeling; leaves open translation to human HF trials.
Rüdebusch et al. (2020) studied Heart failure and pathological cardiac remodelling. Riociguat vs. Vehicle was evaluated on Cardiac function (LV ejection fraction), LV mass to body weight ratio, myocardial fibrosis, and myocyte cross-sectional area. Five weeks of riociguat treatment in mice with established heart failure improved LV ejection fraction and decreased LV mass, myocardial fibrosis, and expression of remodelling genes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: